Predictive Oncology to be acquired by Renovaro

Predictive Oncology (POAI) announced that it has entered into a binding letter of intent with Renovaro (RENB) for Predictive Oncology to be acquired by Renovaro in exchange for preferred stock of Renovaro. Predictive and Renovaro share a commitment to improving outcomes of cancer patients through earlier diagnosis, biomarker discovery and targeted therapies. Further, the companies have proprietary AI / ML platforms with complementary technical advantages that will be leveraged together to accelerate drug discovery and reduce the risk of drug development. Under the terms of the binding letter of intent, Predictive Oncology will be merged into Renovaro in exchange for a newly created series of preferred stock of Renovaro. The preferred stock will be issued to shareholders of Predictive Oncology in a 1:1 exchange for their existing Predictive Oncology common stock.